XML 72 R52.htm IDEA: XBRL DOCUMENT v3.22.2.2
SCHEDULE OF REMUNERATION OF DIRECTORS (Details) - USD ($)
$ in Thousands
 12 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Mar. 31, 2020
IfrsStatementLineItems [Line Items]      
Directors' fees $ 283 $ 158 $ 122
Bonus 75 1,201
[custom:DirectorsSalary] 350 85
Share based payment expenses 1,589 503 41
G Cerrone [member]      
IfrsStatementLineItems [Line Items]      
Directors' fees [1] 164 35  
Bonus [1] 1,160  
[custom:DirectorsSalary] [1]  
Share based payment expenses [1]  
G Jacob [member]      
IfrsStatementLineItems [Line Items]      
Directors' fees [2]  
Bonus [2] 75 41  
[custom:DirectorsSalary] [2] 350 85  
Share based payment expenses [2] 1,579 468  
W Simon [member]      
IfrsStatementLineItems [Line Items]      
Directors' fees 44 42 41
Bonus
[custom:DirectorsSalary]
Share based payment expenses 1 2 4
K Shailubhai [member]      
IfrsStatementLineItems [Line Items]      
Directors' fees [3] 18 37 38
Bonus [3]
[custom:DirectorsSalary] [3]
Share based payment expenses [3] (15) 17 31
J Brancaccio [member]      
IfrsStatementLineItems [Line Items]      
Directors' fees [4] 42 31  
Bonus [4]  
[custom:DirectorsSalary] [4]  
Share based payment expenses [4] 20 16  
G Macrae [member]      
IfrsStatementLineItems [Line Items]      
Directors' fees [5] 13 8
Bonus [5]
[custom:DirectorsSalary] [5]
Share based payment expenses [5]
B Denoyer [member]      
IfrsStatementLineItems [Line Items]      
Directors' fees [6] 15  
Bonus [6]  
[custom:DirectorsSalary] [6]  
Share based payment expenses [6] $ 4  
L Z ambeletti [member]      
IfrsStatementLineItems [Line Items]      
Directors' fees [7]     36
Bonus [7]    
[custom:DirectorsSalary] [7]    
Share based payment expenses [7]     $ 6
[1] Gabriele Cerrone’s bonus awarded for $1,160k was awarded on the basis of the co-invention of the use of Chemerin in the COVID-19 indication when he was not a director or employee of the Company (now the subject of a patent application); work carried out in procuring, backing and completing the refinancing the Company in 2020 and actions taken to make new executive appointments and scientific advisory appointments to the Board with the result that the Company now has a clear and accelerated path to the clinic.
[2] Gary Jacob became an employee and Director of the Company on 7 January 2021
[3] K Shailubhai resigned as Director on 17 June 2021
[4] John Brancaccio was appointed as Director on 10 June 2020
[5] Gregor Macrae was appointed as Director on 18 December 2019 and resigned on 10 June 2020
[6] Bernard Denoyer was appointed as Director on 24 November 2021
[7] Leopoldo Zambeletti resigned as Director on 18 December 2019